肥胖与帕博利珠单抗治疗的子宫内膜癌结局之间的关联
该回顾性研究纳入179例接受帕博利珠单抗治疗的晚期或复发性子宫内膜癌患者,评估肥胖与疗效的关系。较高BMI与更短的无进展生存期相关,在MMRp肿瘤中肥胖者缓解率更低,而MMRd肿瘤各BMI组缓解率均较高;总生存期无显著差异。
要点
- MMRp肿瘤中肥胖(BMI≥30)者缓解率23.4%,低于BMI<30者的40.0%。
- 肥胖与非肥胖组总生存期无显著差异。
核心结论
- 在该种族多样化队列中,肥胖与接受帕博利珠单抗治疗的子宫内膜癌患者更差的无进展生存期相关。
- 肥胖患者的MMRp肿瘤在各亚组中缓解率最低。
- 需要进一步研究并长期随访以阐明肥胖与免疫治疗结局相关的生物学机制。
研究设计与样本
- 回顾性综述,纳入179例接受帕博利珠单抗治疗的晚期或复发性子宫内膜癌患者。
- 收集中位年龄65岁(IQR 58-71岁),平均BMI 33(SD 8.5)。
- 队列包括55例黑人患者(31%)和112例白人患者(63%),99例(55%)为肥胖。
- 46例接受帕博利珠单抗单药治疗,133例接受联合治疗。
- 采用Kaplan-Meier法估计无进展生存期和总生存期,Cox回归建模,log-rank检验评估协变量差异。
主要发现
- 在MMR分层分析中,MMRp肿瘤患者中肥胖(BMI≥30)者缓解率为23.4%,低于BMI<30者的40.0%;MMRd肿瘤各BMI类别缓解率均较高。
- 在帕博利珠单抗联合乐伐替尼亚组(n=79)中,白人和黑人肥胖患者较白人非肥胖患者无进展生存期更差(分别为p=0.021和p=0.035)。
- 肥胖与非肥胖组之间总生存期无显著差异。
局限性
- 原文指出需要进一步研究并长期随访以阐明肥胖与免疫治疗结局相关的生物学机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To determine the association between obesity and pembrolizumab response in racially diverse cohort of patients with advanced and recurrent endometrial cancer (EC). METHODS: We conducted a retrospective review of patients with advanced or recurrent endometrial cancer receiving pembrolizumab. Baseline clinical, demographic and cancer characteristics were collected. Progression free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method and modeled via Cox regression. Covariate differences were assessed using the log-rank test. RESULTS: Among the 179 patients, the median age was 65 years (IQR, 58-71 yrs) and the mean BMI was 33 (SD, 8.5). The cohort consisted of 55 Black patents (31 %) and 112 White patients (63 %); 99 patients (55 %) were obese. Forty-six patients received pembrolizumab alone, and 133 received combination therapy. Higher BMI was associated with shorter PFS (BMI >40: HR 1.91, CI 1.13-3.21, p = 0.014 and BMI 30-40: HR 1.55, CI 1.02-2.35, p = 0.041). In MMR stratified analysis, obesity was associated with lower response rates among patients with MMRp tumors (23.4 %; BMI ≥30 vs 40.0 %; BMI <30), whereas response remained high across BMI categories in MMRd tumors. In the subgroup treated with pembrolizumab and Lenvatinib (n = 79), both White and Black obese experienced worse PFS compared to White non-obese patients (p = 0.021 and p = 0.035, respectively). No significant differences in OS were observed between obese and non-obese groups. CONCLUSIONS: In this diverse cohort, obesity was associated with worse PFS in patients treated with pembrolizumab for EC. MMRp tumors in obese patients had lowest response rates among subgroups. Further studies with long term follow up are needed to elucidate the biological mechanisms linking obesity to immunotherapy outcomes.
引用
- Patterson B, Sinha N, Broaddus E, et al. Associations between obesity and outcomes in pembrolizumab-treated endometrial cancer. Gynecol Oncol. 2025. PMID: 41380305. doi:10.1016/j.ygyno.2025.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。